Current Challenges in Cell Therapy for Neurodegenerative Diseases
-10%
portes grátis
Current Challenges in Cell Therapy for Neurodegenerative Diseases
Lane, Emma L; Lelos, Mariah J; Drew, Cheney J.G.
Elsevier Science & Technology
11/2022
324
Dura
Inglês
9780323989374
15 a 20 dias
Descrição não disponível.
1. Challenges in translating a cell therapy to GMP Gerhard Bauer 2. The challenges in developing a cell therapy for Huntington's disease. Anne Rosser 3. Challenges of cell therapies for retinal diseases Christell Monville 4. Challenges of gene therapy in Huntington's Disease 5. Technological advances and barriers to gene therapy 6. Considerations in the development of cell therapy modulation for spinal cord injury treatment Michael Aron Lane 7. Challenges of developing glial cell therapy for ALS Michal Izrael 8. Exploring cell and gene therapy in current animal models of Parkinson's and Huntington's disease Mariah J. Lelos 9. Considerations for the use of biomaterials to support cell therapy in degenerative disease James Benjamin Phillips 10. Neurosurgical challenges/innovations in cell and gene therapy delivery William Gray 11. Neuroimaging: the challenge of harnessing imaging tools to facilitate cell and gene therapy in neurodegenerative diseases/The contribution and challenges for imaging in advanced therapies of movement disorders 12. Considerations for clinical trial design for novel advanced therapeutics in neurodegenerative disease Cheney Drew and Monica Busse 13. More than a trial participant: The role of the patient in ATMP development and trials for neurodegenerative disease Emma Lane
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Age-related macular degeneration; Animal models; ATMP; Biomaterials; Cell and gene therapy product manufacturing; Cell therapy; Cell transplantation; Cellular engineering; Disease registries; Diversity; Dopamine; Functional recovery; GMP facility design and operation; GMP manufacturing; Good Manufacturing Practice (GMP); Graft; Human embryonic stem cells (hESCs); Human pluripotent stem cells; Huntington's disease; Intra-cranial delivery; Medium spiny neurons; Neural progenitor cells; Neurodegenerative disease; Neuronal stem cells (NSCs); Parkinson's disease; Participant; Participant selection; Pluripotent stem cells; PPIE; Public and patient involvement; Retinitis pigmentosa; Retinopathies; Spinal cord injury; Stem cells; Striatal medium spiny neurons; Tissue engineering; Translation; Transplantation; Trial design
1. Challenges in translating a cell therapy to GMP Gerhard Bauer 2. The challenges in developing a cell therapy for Huntington's disease. Anne Rosser 3. Challenges of cell therapies for retinal diseases Christell Monville 4. Challenges of gene therapy in Huntington's Disease 5. Technological advances and barriers to gene therapy 6. Considerations in the development of cell therapy modulation for spinal cord injury treatment Michael Aron Lane 7. Challenges of developing glial cell therapy for ALS Michal Izrael 8. Exploring cell and gene therapy in current animal models of Parkinson's and Huntington's disease Mariah J. Lelos 9. Considerations for the use of biomaterials to support cell therapy in degenerative disease James Benjamin Phillips 10. Neurosurgical challenges/innovations in cell and gene therapy delivery William Gray 11. Neuroimaging: the challenge of harnessing imaging tools to facilitate cell and gene therapy in neurodegenerative diseases/The contribution and challenges for imaging in advanced therapies of movement disorders 12. Considerations for clinical trial design for novel advanced therapeutics in neurodegenerative disease Cheney Drew and Monica Busse 13. More than a trial participant: The role of the patient in ATMP development and trials for neurodegenerative disease Emma Lane
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
Age-related macular degeneration; Animal models; ATMP; Biomaterials; Cell and gene therapy product manufacturing; Cell therapy; Cell transplantation; Cellular engineering; Disease registries; Diversity; Dopamine; Functional recovery; GMP facility design and operation; GMP manufacturing; Good Manufacturing Practice (GMP); Graft; Human embryonic stem cells (hESCs); Human pluripotent stem cells; Huntington's disease; Intra-cranial delivery; Medium spiny neurons; Neural progenitor cells; Neurodegenerative disease; Neuronal stem cells (NSCs); Parkinson's disease; Participant; Participant selection; Pluripotent stem cells; PPIE; Public and patient involvement; Retinitis pigmentosa; Retinopathies; Spinal cord injury; Stem cells; Striatal medium spiny neurons; Tissue engineering; Translation; Transplantation; Trial design
